Literature DB >> 15677842

Bichat guidelines for the clinical management of brucellosis and bioterrorism-related brucellosis.

Philippe Bossi1, Anders Tegnell, Agoritsa Baka, Frank Van Loock, Jan Hendriks, Albrecht Werner, Heinrich Maidhof, Georgios Gouvras.   

Abstract

Interest in Brucella species as a biological weapon stems from the fact that airborne transmission of the agent is possible. It is highly contagious and enters through mucous membranes such as the conjunctiva, oropharynx, respiratory tract and skin abrasions. It has been estimated that 10-100 organisms only are sufficient to constitute an infectious aerosol dose for humans. Signs and symptoms are similar in patients whatever the route of transmission and are mostly non-specific. Symptoms of patients infected by aerosol are indistinguishable from those of patients infected by other routes. Regimens containing doxycycline plus streptomycin or doxycycline plus rifampin are effective for most forms of brucellosis. Isolation of patients is not necessary. Trimethoprim-sulfamethoxazole and fluoroquinolones also have good results against Brucella, but are associated with high relapse rates when used as monotherapy. The combination of ofloxacin plus rifampicin is associated with good results. Even if there is little evidence to support its utility for post-exposure prophylaxis, doxycycline plus rifampicin is recommended for 3 to 6 weeks.

Entities:  

Mesh:

Year:  2004        PMID: 15677842

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  16 in total

1.  Pathophysiology of the rhesus macaque model for inhalational brucellosis.

Authors:  Lisa N Henning; Stephen M Miller; Dennis H Pak; Amber Lindsay; David A Fisher; Roy E Barnewall; Crystal M Briscoe; Michael S Anderson; Richard L Warren
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

2.  Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; M M Kahl-McDonagh; T A Ficht
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

3.  CD80/CD28 co-stimulation in human brucellosis.

Authors:  P Skendros; P Boura; F Kamaria; M Raptopoulou-Gigi
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

Review 4.  Brucellosis: the case for live, attenuated vaccines.

Authors:  Thomas A Ficht; Melissa M Kahl-McDonagh; Angela M Arenas-Gamboa; Allison C Rice-Ficht
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 5.  Contrasting Lifestyles Within the Host Cell.

Authors:  Elizabeth Di Russo Case; James E Samuel
Journal:  Microbiol Spectr       Date:  2016-02

6.  Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge.

Authors:  M M Kahl-McDonagh; A M Arenas-Gamboa; T A Ficht
Journal:  Infect Immun       Date:  2007-07-30       Impact factor: 3.441

7.  Effect of carbon dioxide on broth microdilution susceptibility testing of Brucella spp.

Authors:  David R Lonsway; Laura A Jevitt; James R Uhl; Franklin R Cockerill; Mary E Anderson; Maureen M Sullivan; Barun K De; Jonathan R Edwards; Jean B Patel
Journal:  J Clin Microbiol       Date:  2009-12-23       Impact factor: 5.948

Review 8.  Laboratory animal models for brucellosis research.

Authors:  Teane M A Silva; Erica A Costa; Tatiane A Paixão; Renée M Tsolis; Renato L Santos
Journal:  J Biomed Biotechnol       Date:  2011-02-20

9.  Immunogenic and invasive properties of Brucella melitensis 16M outer membrane protein vaccine candidates identified via a reverse vaccinology approach.

Authors:  Gabriel Gomez; Jianwu Pei; Waithaka Mwangi; L Garry Adams; Allison Rice-Ficht; Thomas A Ficht
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

Review 10.  Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis.

Authors:  Gabriel Gomez; Leslie G Adams; Allison Rice-Ficht; Thomas A Ficht
Journal:  Front Cell Infect Microbiol       Date:  2013-05-16       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.